Back to Search
Start Over
Stress management at the ER: Regulators of ER stress-induced apoptosis
- Source :
- Pharmacology & Therapeutics. 134:306-316
- Publication Year :
- 2012
- Publisher :
- Elsevier BV, 2012.
-
Abstract
- The endoplasmic reticulum (ER) is an elaborate cellular organelle essential for cell function and survival. Conditions that interfere with ER function lead to the accumulation and aggregation of unfolded proteins which are detected by ER transmembrane receptors that initiate the unfolded protein response (UPR) to restore normal ER function. If the ER stress is prolonged, or the adaptive response fails, apoptotic cell death ensues. Many studies have focused on how this failure initiates apoptosis, particularly because ER stress-induced apoptosis is implicated in the pathophysiology of several neurodegenerative and cardiovascular diseases. In this review we aim to shed light on the proteins that are not core components of the UPR signaling pathway but which can influence the course of the ER stress response by regulating the switch from the adaptive phase to apoptosis. Our research is supported by Science Foundation Ireland (09/RFP/BIC2371; 09/RFP/BMT2153), the Health Research Board (HRA/2009/59) and Breast Cancer Campaign (2008NovPhD21; 2010NovPR13). peer-reviewed
- Subjects :
- XBP1
Unfolded protein response (UPR)
Apoptosis
Models, Biological
03 medical and health sciences
0302 clinical medicine
Bcl-2 family
Animals
Humans
Pharmacology (medical)
ASK1
030304 developmental biology
Pharmacology
0303 health sciences
Chemistry
Endoplasmic reticulum
Endoplasmic Reticulum Stress
3. Good health
XIAP
Cell biology
Endoplasmic reticulum (ER) stress
030220 oncology & carcinogenesis
Unfolded Protein Response
Unfolded protein response
Signal transduction
Signal Transduction
Subjects
Details
- ISSN :
- 01637258
- Volume :
- 134
- Database :
- OpenAIRE
- Journal :
- Pharmacology & Therapeutics
- Accession number :
- edsair.doi.dedup.....affe26d5ec1284c38d2865e2818e36a4
- Full Text :
- https://doi.org/10.1016/j.pharmthera.2012.02.003